Our Company has been granted patents for our products in twenty-six countries, namely Singapore, Australia, New Zealand, China, Malaysia, Japan, Indonesia, South Korea, Canada, South Africa and the European Union (Germany, France, United Kingdom, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland and Finland). Further, we have applications pending in major markets, including the US, India, Hong Kong, and Thailand.
The claims of the patents cover a fast-dissolving oral dosage form for the release of a biologically active material in the oral cavity. Additionally, the particular dosage form may contain and deliver a wide range of biologically active materials and is not limited to a specific biologically active material. Methods for the production of the fast dissolving oral dosage form are also provided. See more on our WaferiX™ technology here.
Our patents strategy includes the use of the Patent Cooperation Treaty system with a view to obtain broad protection for our patent portfolio, which covers WaferiX™ technology, our products as well as potential new formulations. We aim to secure intellectual property protection for our invention and products in all relevant jurisdictions, as and when necessary. In most countries, the term awarded for a granted patent is 20 years from the date of application.